TNF and colorectal cancer: In breast cancer, andrographolide has been shown to inhibit COX-2 expression by reducing p300 HAT activity and impede angiogenesis via the VEGF pathway [8]; in human colorectal cancer HCT116 cells, andrographolide acts as an antagonist of TNF-α-induced IL-8 production [9].